Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

• Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
• Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
• Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
• Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
• Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
• Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
• Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications